Safety and Efficacy of Resveratrol in Healing of Maxillofacial Fractures: A Randomized Controlled Study

Shivkumar Chopane; Kirti Chaudhry; Aakash Kohli; Surjit Singh; Mithu Banerjee; Pravin Kumar; Aparna Ganesan; Ankita Chugh

doi:10.1007/s12663-023-01992-7

Safety and Efficacy of Resveratrol in Healing of Maxillofacial Fractures: A Randomized Controlled Study

J Maxillofac Oral Surg. 2023 Dec;22(4):987-994. doi: 10.1007/s12663-023-01992-7. Epub 2023 Sep 7.

Authors

Shivkumar Chopane¹, Kirti Chaudhry², Aakash Kohli², Surjit Singh³, Mithu Banerjee⁴, Pravin Kumar⁵, Aparna Ganesan¹, Ankita Chugh²

Affiliations

¹ Department of Oral and Maxillofacial Surgery, All India Institute of Medical Sciences, Jodhpur, India.
² Oral and Maxillofacial Surgery, Department of Dentistry, All India Institute of Medical Sciences, Jodhpur, India.
³ Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
⁴ Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India.
⁵ Department of Dentistry, All India Institute of Medical Sciences, Jodhpur, India.

PMID: 38105826
PMCID: PMC10719438 (available on 2024-12-01)
DOI: 10.1007/s12663-023-01992-7

Abstract

Objectives: To assess the efficacy of resveratrol in improving functional outcomes following open reduction and internal fixation of maxillofacial fractures.

Study design: A single-center, randomized, parallel group, prospective, double-blind clinical trial was conducted on 40 patients between the age 20 and 60 years, requiring open reduction and internal fixation of maxillofacial fractures. The selected patients were randomly divided into two groups, Group 1 (placebo) and Group 2 (resveratrol) where tablets resveratrol 500 mg were given twice daily for 1 month following open reduction and internal fixation of fractured segments. Bite force was calculated pre-operatively and on the 1st, 4th, 8th and 12th week postoperatively. Serum markers osteocalcin and alkaline phosphate were calculated pre-operatively and at 4th and 12th week postoperatively.

Results: Bite force (690.55 ± 262.00) in the resveratrol group was higher than the placebo group (553.27 ± 300.08) at 12th week postoperatively. However, the difference was non-significant statistically (p = 0.132). Resveratrol group (116.80 ± 55.25) showed better maintenance of serum ALP level as compared to placebo group (107.90 ± 42.99) at 12th week postoperatively, but again it lacked statistical significance (p = 0.573). Resveratrol group after initial reduction at 4th week showed serum osteocalcin levels nearly equal to the preoperative values at 12th week, while the placebo group showed a decline both at 4th and 12th week postoperatively. However, these results were not statistically significant (p = 0.065).

Conclusion: There was no statistically significant difference in bite force, serum ALP level and serum osteocalcin levels between placebo group and resveratrol group. Though not statistically significant but early increased level of serum osteogenic markers, better restoration of bite force in group 2 (tab. Resveratrol) indicates toward its possible optimistic role in maxillofacial fracture healing. More studies with larger sample sizes are needed in order to confirm the efficacy of this drug in maxillofacial fracture.

Keywords: Bite force; Resveratrol; Serum alkaline phosphatase; Serum osteocalcin.

© The Association of Oral and Maxillofacial Surgeons of India 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.